Savara Inc. Common Stock
(NASDAQ:SVRA)
Description
Savara Inc. operates as an orphan lung disease company. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
SVRA Overview
None
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$3.4300 |
Previous Close Volume |
370290 |